140 related articles for article (PubMed ID: 11903102)
21. The medical treatment of patients with Parkinson's disease receiving subthalamic neurostimulation.
Alexoudi A; Shalash A; Knudsen K; Witt K; Mehdorn M; Volkmann J; Deuschl G
Parkinsonism Relat Disord; 2015 Jun; 21(6):555-60; discussion 555. PubMed ID: 25842260
[TBL] [Abstract][Full Text] [Related]
22. The long-duration response to levodopa: phenomenology, potential mechanisms and clinical implications.
Anderson E; Nutt J
Parkinsonism Relat Disord; 2011 Sep; 17(8):587-92. PubMed ID: 21530356
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of levodopa/carbidopa delivered from gastric-retentive extended-release formulations in patients with Parkinson's disease.
Chen C; Cowles VE; Sweeney M; Stolyarov ID; Illarioshkin SN
J Clin Pharmacol; 2012 Jul; 52(7):1069-77. PubMed ID: 21610205
[TBL] [Abstract][Full Text] [Related]
24. Central levodopa influx and the clinical motor response to levodopa in patients with Parkinson disease complicated with motor fluctuations and dyskinesias.
López-Ariztegui N; Arévalo MA; de Ceballos ML; Grandas F
Clin Neuropharmacol; 2009; 32(6):321-5. PubMed ID: 19667975
[TBL] [Abstract][Full Text] [Related]
25. Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.
Olanow CW
Mov Disord; 2008; 23 Suppl 3():S613-22. PubMed ID: 18781663
[TBL] [Abstract][Full Text] [Related]
26. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetic optimisation in the treatment of Parkinson's disease.
Contin M; Riva R; Albani F; Baruzzi A
Clin Pharmacokinet; 1996 Jun; 30(6):463-81. PubMed ID: 8792058
[TBL] [Abstract][Full Text] [Related]
28. [Inter- and intraindividual pharmacokinetic variations in the treatment of Parkinson's disease].
Nomoto M; Nakatsuka A; Nagai M; Yabe H; Moritoyo T; Moritoyo H; Nisikawa N
Rinsho Shinkeigaku; 2005 Nov; 45(11):895-8. PubMed ID: 16447756
[TBL] [Abstract][Full Text] [Related]
29. When and how should treatment be started in Parkinson disease?
Lang AE
Neurology; 2009 Feb; 72(7 Suppl):S39-43. PubMed ID: 19221313
[TBL] [Abstract][Full Text] [Related]
30. Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease.
Rascol O; Nutt JG; Blin O; Goetz CG; Trugman JM; Soubrouillard C; Carter JH; Currie LJ; Fabre N; Thalamas C; Giardina WW; Wright S
Arch Neurol; 2001 Feb; 58(2):249-54. PubMed ID: 11176963
[TBL] [Abstract][Full Text] [Related]
31. Levodopa and the progression of Parkinson's disease.
Walton-Hadlock JL
N Engl J Med; 2005 Mar; 352(13):1386; author reply 1386. PubMed ID: 15800240
[No Abstract] [Full Text] [Related]
32. A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion.
Westin J; Nyholm D; Pålhagen S; Willows T; Groth T; Dougherty M; Karlsson MO
Clin Neuropharmacol; 2011; 34(2):61-5. PubMed ID: 21297456
[TBL] [Abstract][Full Text] [Related]
33. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
34. The effect of levodopa dose and body weight on dyskinesia in a prevalent population of people with Parkinson's disease.
Walker RW; Howells AR; Gray WK
Parkinsonism Relat Disord; 2011 Jan; 17(1):27-9. PubMed ID: 21051272
[TBL] [Abstract][Full Text] [Related]
35. Levodopa "drug holiday" with amantadine infusions as a treatment of complications in Parkinson's disease.
Koziorowski D; Friedman A
Mov Disord; 2007 May; 22(7):1033-6. PubMed ID: 17370308
[TBL] [Abstract][Full Text] [Related]
36. The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. Parkinson Study Group.
Clin Neuropharmacol; 1999; 22(4):220-5. PubMed ID: 10442252
[TBL] [Abstract][Full Text] [Related]
37. Controlled-release levodopa/carbidopa. III: Sinemet CR5 treatment of response fluctuations in Parkinson's disease.
Cedarbaum JM; Hoey M; Kutt H; McDowell FH
Clin Neuropharmacol; 1988 Apr; 11(2):168-73. PubMed ID: 3378225
[TBL] [Abstract][Full Text] [Related]
38. [Influence of levodopa, stalevo on dyskinesia in Parkinson's disease: STRIDE-PD study].
Liashchenko EA; Skripkina NA; Levin OS
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):62-8. PubMed ID: 23994933
[TBL] [Abstract][Full Text] [Related]
39. The future of pharmacogenetics in Parkinson's disease treatment.
Hutz MH; Rieder CR
Pharmacogenomics; 2018 Feb; 19(3):171-174. PubMed ID: 29191064
[No Abstract] [Full Text] [Related]
40. Risk of Disabling Response Fluctuations and Dyskinesias for Dopamine Agonists Versus Levodopa in Parkinson's Disease.
Haaxma CA; Horstink MW; Zijlmans JC; Lemmens WA; Bloem BR; Borm GF
J Parkinsons Dis; 2015; 5(4):847-53. PubMed ID: 26444087
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
